Bioxodes’ Post

🧬 Discover at INASL 2024 from August 7-10 to explore our poster presentation titled "One-step non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis and fibrosis in high-risk population" using the OWLiver test. This innovative approach aims to improve the accuracy and ease of diagnosing these conditions, offering significant benefits for patient care and management. Our test demonstrates high sensitivity (86.1%) and positive predictive value (85.3%) for detecting MASH. The OWLiver Panel shows reliable accuracy in identifying MASH and significant fibrosis among high-risk individuals. This advancement in non-invasive diagnostics can revolutionize how we approach liver health and patient care.🔬 🗣️ Don't miss this opportunity to learn more about how our work can impact liver health and the future of medical diagnostics during the oral presentation of the poster on the Session - Special Interest Group (SIG) – MASLD the 9th August from 8:00 AM – 8.50 AM in Hall – 1. #INASL2024 #LiverHealth #Metabolomics #MedicalInnovation #Healthcare

Latest figures out of the UK have found more than 6000 people are currently waiting for a kidney transplant, the highest level in 10 years, with experts concerned the number of people needing a kidney replacement will continue to rise due to increasing cases of type 2 diabetes. Proteomics International’s Managing Director Dr Richard Lipscombe highlighted how Australia can and should be learning lessons from UK’s kidney disease crisis in the December edition of Medical Forum Magazine, outlining the importance of developing diagnostic and prognostic tools to assist in the prevention and early diagnosis of this disease. Proteomics International are proud to play a role in the fight to reduce the negative impact of chronic kidney disease in type 2 diabetics. PromarkerD can predict disease onset up to four years in advance, enabling timely treatment before kidney function loss occurs. You can read Richard’s piece in full online at the Medical Forum Magazine - https://lnkd.in/g8cxtiVU You can read more about the latest figures out of the UK here - https://lnkd.in/gYiJUuJj #diabetes #kidneyhealth #Type2Diabetes #DiabeticKidneyDisease #PromarkerD #DiagnosticInnovation #prognostics #PIQ #EarlyDiseaseDetection #DiabetesManagement 

Transforming the way we approach fatty liver disease isn't just about better diagnostics—it's about redefining patient care for a healthier tomorrow. 🌟 The shift from NAFLD to MAFLD in medical terminology not only marks a pivotal change in our understanding but also highlights the critical role of metabolic dysfunction in this condition, underlining the importance of personalized treatment strategies. At Arrow Dx, we're not just diagnosing fatty liver disease early; we're tailoring interventions to individual metabolic profiles, pioneering a future where care is as unique as each patient's DNA. 🧬💡 This terminology change from NAFLD to MAFLD is not just semantic; it signifies a deeper comprehension of the disease and a more focused approach to treatment. Dive deeper into how biotech innovations are paving the way for personalized medicine in our latest blog. Read now: https://lnkd.in/edAvAiqc #FattyLiverDisease #PersonalizedMedicine #ArrowDxInnovation

Our latest research uncovers the pivotal role of IL-18 in liver fibrosis. Discover how IL-18 impacts hepatic stellate cells (HSCs) and drives liver cirrhosis. This groundbreaking study sheds light on potential treatments for fibrosis. 👉 Read the full findings here: https://ow.ly/LYL150QCh1l #LiverHealth #Research #FibrosisTreatment #UCSD #UCSDHealth #UCSDACTRI

📑 #NoteworthyPublication! 📊🔬 The ability of hemoglobin to bind and release oxygen is vital for tissue oxygenation and is influenced by various physiological and pathological factors. The study we promote today came out from Wroclaw Medical University and was aimed to assess the impact of hemodialysis on #p50 in chronic kidney disease (CKD) patients, while also examining the correlation between p50, erythropoiesis, point-of-care testing (POCT), and other lab parameters. The paper was reviewed by Dr. Juan Torras, an expert with over 25 years of experience in experimental studies and clinical trials in renal diseases. We are also grateful to Dr. Kenji Tsuji for his meticulous guest-editing. 🔗 For more details, read the full paper: https://lnkd.in/ddKf72S4 #Hemodialysis #CKD #HealthcareResearch #MedicalScience #Diagnostics

I am thrilled to share about Cytosorb, a cutting-edge blood purification technology, is making strides in healthcare, potentially revolutionizing the management of severe pancreatitis! Pancreatitis, characterized by pancreatic inflammation and systemic complications, presents significant challenges in patient care. But with Cytosorb, we're tackling these obstacles head-on. Our innovative technology effectively removes pro-inflammatory cytokines and mediators from the bloodstream, addressing the root cause of systemic inflammation and organ dysfunction. By reducing circulating inflammatory molecules, Cytosorb offers new hope for patients battling severe pancreatitis, improving outcomes and enhancing quality of life. While our journey continues, we're committed to advancing the field of critical care medicine and delivering transformative solutions to healthcare professionals worldwide. Join us in shaping the future of patient care with Cytosorb! #HealthcareInnovation #Cytosorb #PancreatitisManagement #CriticalCareMedicine #TransformingPatientOutcomes

Here’s a simulation of my own beating heart, developed by ELEM Biotech Why are we developing Virtual Human Twins, and in particular #VirtualHearts? ❤️ As the World Heart Federation highlights, cardiovascular disease (CVD) is the leading cause of death worldwide, with more than 20.5 million every year. Replicating the complex environment of CVD for drug testing is a major challenge due to its heterogeneity (different comorbidities and differences in age and gender affect drug incidence) and its progressive nature, which makes it difficult to predict long-term responses based on short-term trial data. I am part of the development team at ELEM, and our mission is to bring to our customers the power of ELEM's Virtual Human Twins technology, enabling Pharma companies to conduct in-silico trials for cardiac safety in large and heterogenuous populations, helping them in their drug development, approval and study. 🌍 Want to join the fight against CVD? Help spread awareness of its impact and the small lifestyle changes—better diet, exercise, and stress management—that can improve heart health! #CardiovascularHealth #UseHeart #VirtualHumanTwins #SMARTtrials #UseVirtualHearts

Dear Colleagues, Recent research published in Medical Science Monitor sheds light on the association of CD4+/CD8+ T cell ratio and platelet/lymphocyte ratio (PLR) with long-term infection and chronic renal insufficiency in kidney transplant recipients (KTRs). The study found that PLR and CD4+/CD8+ were risk factors for these complications ([i]P[/i]<0.05). This valuable insight can aid in identifying patients at higher risk and guide preventive strategies. Understanding the correlation between these ratios and complications can help improve patient outcomes and long-term prognosis. To delve deeper into this important topic, the complete report is now available on the Medical Science Monitor webpage. #research #kidneytransplant #medicalscience | https://lnkd.in/dCPcETxZ

🌏 Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial was presented yesterday at #ESCCongress and published in THE LANCET (https://lnkd.in/ejdM2EM2). 🎉 Congratulations: Prof Ling Tao, Chao Gao, Patrick W. Serruys, Yoshinobu Onuma and all REC-CAGEFREE I Investigators ! The present study is the first RCT with a large population and powered clinical endpoints to investigate DCB versus DES in patients with de novo CAD, regardless of target vessel diameter.

Sepsis is a major global healthcare challenge.¹ Recent scientific developments provide rationale for hemoadsorption in patients with sepsis.² Adsorption is a process by which molecules are removed from the blood by binding to a membrane or other adsorbing substances.³ Hemoadsorption (formerly referred to as hemoperfusion) is the passage of blood through asorbent-containing cartridge or a hemofilter for selective or broad-spectrum solute removal via direct contact of the blood with the sorbent material or the filter membrane surface.⁴ Understanding of hemoadsorption provided by the 30th ADQI consensus conference is intended to guide the practice and research in the field.² Studies of endotoxin-based hemoadsorption have identified possible target phenotypes for larger RCTs.² As your partner, Baxter is committed to identifying sepsis and innovating for improved sepsis management. Learn more: https://lnkd.in/g7KPHCuH References: 1. Rudd KE, et al. Lancet. 2020; 395:200-211. 2. Bellomo R, et al. Nephrol Dial Transplant. 2024 Apr 15:gfae089. Epub ahead of print. 3. Neri M, et al. CritCare. 2016; 20:318. 4. Ostermann M, et al. Blood Purif 2023. Online ahead of print. #Baxter #Sepsis #AcuteTherapies